Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma

医学 阿帕蒂尼 不利影响 内科学 阶段(地层学) 进行性疾病 胃肠病学 栓塞 外科 总体生存率 疾病 生物 古生物学
作者
Guohui Xu,Jun Zhu,Xiaoqian Xu,Yaoyong Chen,Qiang Wang,Quanji Yue,Kaijian Lei,Yuming Jia,Guo Xiao
出处
期刊:Journal of Cancer Research and Therapeutics [BioMed Central]
卷期号:18 (5): 1432-1432 被引量:4
标识
DOI:10.4103/jcrt.jcrt_2401_21
摘要

To evaluation the clinical efficacy and safety of bronchial artery chemoembolization (BACE) combined with apatinib for treatment of advanced central lung squamous cell carcinoma (LSCC).Forty-seven patients with pathologically diagnosed stage IIIB or IV central LSCC that was not resectable were selected among hospital patients presenting after November 2016. Twenty-one patients were treated with BACE combined with apatinib; the remaining patients served as a control group treated with BACE alone. Objective response rate (ORR) and disease control rate (DCR) were evaluated with postoperative contrast-enhanced CT scans at 3, 6, and 12 months. Progression-free survival (PFS) curves were used to evaluate curative effects. Adverse events were recorded to assess safety.BACE operations were successfully completed in all 47 patients. Significant differences were found at six and 12 months (P < 0.05). Median PFS was 322 days in the observation group and 209 days in the control group: a statistically significant difference (P = 0.042). One-year survival rates were 76.19% and 46.15% for observation and control patients, respectively; this difference was also significant (P = 0.037). Three patients in the observation group received emergency interventional embolization for hemoptysis, and patients with grade III or greater adverse reaction events (AE) accounted for 19.05% of patients (4/21); these subjects improved or were controlled after active treatment.BACE combined with apatinib is effective for treatment of advanced central LSCC, with definite short-term efficacy, controllable risk, and high safety. Investigation with a larger sample size is warranted to confirm study results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
cc完成签到,获得积分10
1秒前
司_完成签到,获得积分20
1秒前
coldyy1发布了新的文献求助10
1秒前
Rondab应助go采纳,获得10
1秒前
yanglinhai完成签到 ,获得积分10
1秒前
qqq完成签到,获得积分10
2秒前
adgcxvjj发布了新的文献求助10
3秒前
斯文败类应助哈哈哈哈哈采纳,获得10
3秒前
3秒前
赵馨儿完成签到,获得积分10
3秒前
ddd发布了新的文献求助10
3秒前
科研小垃圾完成签到,获得积分10
3秒前
龙辉完成签到,获得积分10
3秒前
最後まで发布了新的文献求助10
4秒前
WEI发布了新的文献求助10
4秒前
Rando发布了新的文献求助10
5秒前
JiaxinChen完成签到,获得积分10
5秒前
干净怀寒完成签到,获得积分20
5秒前
酷酷的冰真应助cc采纳,获得20
5秒前
5秒前
5秒前
南国完成签到,获得积分10
5秒前
zy发布了新的文献求助10
6秒前
JCX完成签到,获得积分20
6秒前
dameinv完成签到 ,获得积分10
6秒前
搜集达人应助save采纳,获得10
6秒前
w1完成签到,获得积分10
6秒前
复杂的海完成签到,获得积分10
6秒前
欢喜的小珍完成签到 ,获得积分10
6秒前
愉快的戎完成签到,获得积分10
6秒前
8秒前
Reeee完成签到 ,获得积分10
8秒前
林佳一完成签到,获得积分10
8秒前
沉静的万天完成签到 ,获得积分10
9秒前
9秒前
9秒前
千宝发布了新的文献求助10
9秒前
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969322
求助须知:如何正确求助?哪些是违规求助? 3514152
关于积分的说明 11172188
捐赠科研通 3249407
什么是DOI,文献DOI怎么找? 1794832
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804781